Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ProKidney Corp. (PROK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PROK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 4 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.96% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.81B USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 7 | Beta 1.81 | 52 Weeks Range 0.46 - 5.95 | Updated Date 08/15/2025 |
52 Weeks Range 0.46 - 5.95 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.15 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -17967.87% |
Management Effectiveness
Return on Assets (TTM) -25.3% | Return on Equity (TTM) -40.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32563875 | Price to Sales(TTM) 3438 |
Enterprise Value 32563875 | Price to Sales(TTM) 3438 | ||
Enterprise Value to Revenue 61.79 | Enterprise Value to EBITDA 2.13 | Shares Outstanding 133419000 | Shares Floating 82146052 |
Shares Outstanding 133419000 | Shares Floating 82146052 | ||
Percent Insiders 28.84 | Percent Institutions 33.44 |
Upturn AI SWOT
ProKidney Corp.
Company Overview
History and Background
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease (CKD). Founded to address the limitations of current CKD treatments, ProKidney's lead product is REACT, a genetically modified autologous renal progenitor cell therapy.
Core Business Areas
- Cell Therapy Development: Focused on the development and commercialization of REACT, a cell therapy for treating CKD.
Leadership and Structure
Key leadership includes the CEO, CFO, and Chief Medical Officer. The organizational structure is typical of a clinical-stage biotech company, emphasizing R&D, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- REACT: REACT is a genetically modified autologous renal progenitor cell therapy in Phase 3 clinical trials for CKD. No current market share data as it's not commercialized. Competitors include companies developing other novel CKD therapies.
Market Dynamics
Industry Overview
The CKD treatment market is large and growing, driven by an aging population and increasing prevalence of diabetes and hypertension. Current treatments primarily address symptoms but do not reverse disease progression. Significant unmet need remains.
Positioning
ProKidney aims to disrupt the CKD market with a potentially disease-modifying cell therapy. Their competitive advantage lies in REACT's unique mechanism of action.
Total Addressable Market (TAM)
The estimated TAM for CKD treatments is substantial, potentially exceeding $80 billion globally. ProKidney is targeting a significant portion of this market with REACT.
Upturn SWOT Analysis
Strengths
- Novel Cell Therapy Approach
- Proprietary Technology Platform
- Experienced Management Team
Weaknesses
- Clinical Trial Risk
- Regulatory Uncertainty
- Reliance on Single Product
Opportunities
- Positive Clinical Trial Results
- Partnerships with Pharmaceutical Companies
- Expansion into New CKD Indications
Threats
- Competition from Established Therapies
- Unfavorable Regulatory Decisions
- Clinical Trial Failures
Competitors and Market Share
Key Competitors
- VRTX
Competitive Landscape
ProKidney competes with companies developing both novel and established CKD therapies. Their advantage lies in a potentially disease-modifying approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the progress of REACT through clinical trials and the ability to raise capital.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing Phase 3 trials for REACT and exploring partnerships.
Summary
ProKidney is a high-risk, high-reward clinical-stage biotech company targeting a large and underserved CKD market. The success of the company is highly dependent on the clinical trials of REACT. Key areas of focus include clinical trial execution, regulatory approvals, and successful commercialization. ProKidney's novel cell therapy approach has the potential to disrupt the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Data may be outdated. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProKidney Corp.
Exchange NASDAQ | Headquaters Winston-Salem, NC, United States | ||
IPO Launch date 2022-07-12 | CEO & Director Dr. Bruce Culleton M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 204 | Website https://prokidney.com |
Full time employees 204 | Website https://prokidney.com | ||
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.